Albert Labs announces Strategic Investment from Cantheon Capital LLC for First In-Human TrialsMindMed Reports Full Year 2022 Financial Results and Business HighlightsCybin to Participate in the Oppenheimer 33rd Annual Healthcare ConferenceNuminus to Participate in the Sequire Cannabis & Psychedelics Conference on Wednesday, April 5, 2023Braxia Scientific Provides Update on Proposed Irwin Transaction; Company Retains Strategic Clinical Assets and Ketamine Numinus Announces Four Peer-Reviewed Publications from its Chief Clinical Officer in 2023Irwin Naturals Signs Letter of Intent to Acquire Braxia ScientificNuminus Wellness Inc. Reports Q1 2023 ResultsIrwin Naturals and Braxia Scientific Announce Partnership for In-Human Clinical Studies Supporting Pharmaceutical CompanNuminus Develops Mushroom Tea for Use in Psychedelic ResearchIs the Psychedelic Sector Poised for a Comeback?!?PSYC + Nucleus Form New Partnership to Develop and Launch Psychedelic FinderWhat You Need to Know About Numinus Wellness…Numinus provides update on acquisition integration and announces new client financing optionsPSYC Corp’s Psychedelic Spotlight Surpasses One Million Page Views for Fourth Consecutive MonthNuminus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022The Psychedelic Sector is Quietly Outperforming the S&P 500PSYC Completes and Publishes 2021 Audited Financials; Will Begin Audit of Q1 & Q2 2022Numinus to Participate in the H.C. Wainwright 24th Annual Global Investment Conference on September 12-14, 2022PSYC’s Bonfire Platform Development Progresses; Will Host Free Virtual Community Event on August 29th

Canadian Stocks Trade Higher After Constellation Invests $245 Million into Canopy Growth

Oct 30, 2017 • 1:59 PM EDT
Stock Chartt.jpg
2 MIN READ  •  By Michael Berger
Share Share - Facebook Share - Twitter

Canopy Growth (WEED.TO) (TWMJF) is surging higher after Constellation Brands (STZ: NYSE) acquired 9% of the Canadian licensed cannabis producer for $245 million (CAD).

This purchase was completed at a premium to Canopy’s closing price on Friday and the transaction is expected to close during the third quarter of fiscal 2018. Canopy sold 18.9 million shares at $12.9783 per share and will the proceeds to fund its international expansion program.

This development has caught the attention of mainstream financial media and Canadian licensed medical marijuana producers are trading higher off this news.

While this development was nothing short of a game-charger for the legal marijuana industry, it is not the only exciting development to take place today. We want to highlight three Canadian cannabis updates that investors should be aware of.

Aurora Cannabis Receives Grow License from Health Canada

Aurora Cannabis (ACB.TO) (ACBFF) is trading higher after the company announced that the 40,000 sq. ft. indoor production facility in Pointe-Claire, Quebec has received its cultivation license from Health Canada. The newly licensed facility, to be known as Aurora Vie, makes Aurora the 2nd licensed producer in Quebec, Canada’s second most populous province. Initially, genetics (clones) will be transferred from the Aurora Mountain facility and the company anticipates first harvest in the first calendar quarter of 2018.

In April, Aurora acquired the facility for $7 million (80% complete at the time). The facility has been completed, with approx. $3 million in configuration and technology upgrades specifically designed to meet European Union (EU) Good Manufacturing Practices (GMP) certification standards. Aurora Vie has a projected cultivation capacity of approximately 4,000 kg per year.

Emblem Appoints a New CEO

Emblem Corp. (EMC.V) (EMMBF) is trading higher after the company announced the appointment of Nick Dean as the new Chief Executive Officer effective no later than January 15, 2018. Dean succeeds Gordon H. Fox, who has been with Emblem since its inception.

Emblem’s Board of Directors is confident this change in leadership will build on the current success and enhance its position as a leader in the Canadian cannabis market. Fox joined Emblem in 2013 and assumed the role of CEO in 2015.

Canaccourd Genuity Downgrades Maricann Group

On Friday, Maricann Group Inc. (MARI.CN) (MRRCF) closed a $31 million private placement of convertible debenture units as well as the acquisition of NanoLeaf Technologies Inc., a biotech firm with licensing rights to patented nano-technology for ingestible cannabinoid delivery called VESIsorb.

Today, Maricann is trading higher off the Canopy news and the market seems to be shaking off the downgrade from Canaccourd Genuity. Earlier today, Canaccord cut its price target on Maricann from $5 to $4.25. 

Share Share - Facebook Share - Twitter


Authored By

Michael Berger

Michael Berger is Managing Partner of StoneBridge Partners, LLC and Founder of Prior to entering the cannabis industry, Michael was an Equity Research Analyst at Raymond James Financial covering the Energy Sector. Michael has been featured in publications such as The Street, Bloomberg, US Money News, and hosts various cannabis events across North America.


Top Stories

Get the Latest Cannabis News & Stock Picks.

Enter your email below to join the official Mushroomstocks newsletter.

 All good -- no spamming here.

The psychedelics sector is starting to take off as smart money begins to position itself across the industry.

Stay updated with all latest updates,upcoming events & much more.